Since the first report in 2003,
bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been increasing, without effective clinical strategies.
Osteoporosis is common in elderly women, and
bisphosphonates (BPs) are typical and widely used anti-osteoporotic or anti-bone-resorptive drugs. BRONJ is now a serious concern in dentistry. As BPs are
pyrophosphate analogues and bind strongly to bone
hydroxyapatite, and the P-C-P structure of BPs is non-hydrolysable, they accumulate in bones upon repeated administration. During
bone-resorption, BPs are taken into osteoclasts and exhibit cytotoxicity, producing a long-lasting anti-bone-resorptive effect. BPs are divided into
nitrogen-containing BPs (N-BPs) and non-
nitrogen-containing BPs (non-N-BPs). N-BPs have far stronger anti-bone-resorptive effects than non-N-BPs, and BRONJ is caused by N-BPs. Our murine experiments have revealed the following. N-BPs, but not non-N-BPs, exhibit direct and potent inflammatory/necrotic effects on soft-tissues. These effects are augmented by
lipopolysaccharide (the inflammatory component of bacterial cell-walls) and the accumulation of N-BPs in jawbones is augmented by
inflammation. N-BPs are taken into soft-tissue cells via
phosphate-transporters, while the non-N-BPs
etidronate and
clodronate inhibit this transportation.
Etidronate, but not
clodronate, has the effect of expelling N-BPs that have accumulated in bones. Moreover,
etidronate and
clodronate each have an
analgesic effect, while
clodronate has an anti-inflammatory effect via inhibition of
phosphate-transporters. These findings suggest that BRONJ may be induced by
phosphate-transporter-mediated and
infection-promoted mechanisms, and that
etidronate and
clodronate may be useful for preventing and treating BRONJ. Our clinical trials support
etidronate being useful for treating BRONJ, although additional clinical trials of
etidronate and
clodronate are needed.